Upstream Bio (NASDAQ:UPB – Get Free Report) and MediWound (NASDAQ:MDWD – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Profitability
This table compares Upstream Bio and MediWound’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Upstream Bio | -5,712.33% | -57.09% | -54.69% |
| MediWound | -234.98% | -58.44% | -29.62% |
Insider and Institutional Ownership
46.8% of MediWound shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and target prices for Upstream Bio and MediWound, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Upstream Bio | 1 | 2 | 4 | 0 | 2.43 |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
Upstream Bio currently has a consensus price target of $26.67, suggesting a potential upside of 859.23%. MediWound has a consensus price target of $33.00, suggesting a potential upside of 155.81%. Given Upstream Bio’s higher probable upside, research analysts plainly believe Upstream Bio is more favorable than MediWound.
Valuation and Earnings
This table compares Upstream Bio and MediWound”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Upstream Bio | $2.85 million | 53.46 | -$143.44 million | ($3.02) | -0.92 |
| MediWound | $16.96 million | 9.90 | -$23.88 million | ($1.80) | -7.17 |
MediWound has higher revenue and earnings than Upstream Bio. MediWound is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Upstream Bio has a beta of 1.6, suggesting that its stock price is 60% more volatile than the S&P 500. Comparatively, MediWound has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500.
Summary
MediWound beats Upstream Bio on 7 of the 12 factors compared between the two stocks.
About Upstream Bio
Upstream Bio is a clinical-stage biopharmaceutical company developing treatments for inflammatory diseases. The company is based in Waltham, Massachusetts, and its research focuses on pathways involved in immune and inflammatory responses. Its lead product candidate, verekitug (UPB-101), is an antibody designed to block the receptor for thymic stromal lymphopoietin, a protein associated with inflammation. Upstream Bio is developing verekitug for conditions including asthma and chronic rhinosinusitis with nasal polyps.
About MediWound
MediWound Ltd. is an Israeli biotechnology company that develops topical enzymatic treatments for tissue repair. Its products are designed to remove damaged tissue and support care for patients with burns and chronic wounds. The company’s lead product, NexoBrid, is a bromelain-based treatment used to remove dead tissue from deep thermal burns. It has received regulatory approvals in the United States and other markets. In the United States, MediWound works with Vericel to commercialize the product.
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
